| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 1.837 | 0 | 276 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Income - EUR | 9.823 | 0 | 276 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Expenses - EUR | 2.349 | 966 | 0 | 2.520 | 0 | 0 | 0 | 3 | 3 | 3 |
| Gross Profit/Loss - EUR | 7.474 | -966 | 276 | -2.520 | 0 | 0 | 0 | -3 | -3 | -3 |
| Net Profit/Loss - EUR | 7.179 | -966 | 268 | -2.520 | 0 | 0 | 0 | -3 | -3 | -3 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Rhinospot Med S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Assets | 2.462 | 2.510 | 2.735 | 5 | 5 | 5 | 5 | 2 | 2 | 2 |
| Inventories | 2.025 | 2.005 | 1.971 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 351 | 400 | 393 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Cash | 85 | 105 | 372 | 3 | 3 | 3 | 3 | 0 | 0 | 0 |
| Shareholders Funds | -59.086 | -59.450 | -58.176 | -39.898 | -39.125 | -38.383 | -37.532 | -37.792 | -37.677 | -37.466 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 61.704 | 62.113 | 61.063 | 40.052 | 39.276 | 38.531 | 37.677 | 37.794 | 37.679 | 37.468 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4646 - 4646" | |||||||||
| CAEN Financial Year |
4646
|
|||||||||
Comments - Rhinospot Med S.r.l.